Ir Professor Ping-kong Alexander WAI, Vice President (Research Development) of PolyU (front row, center); Dr Johnson LAU, Chairman and CEO of Athenex, Inc. (front row, left); and Mr YongHui WANG, Chairman and CEO of Xiangxue Pharmaceutical and CEO of Xiangxue Life Sciences (front row, right) sign the MoU for setting up the PolyU—Axis Therapeutics Joint Center for Immunotherapy
Professor Larry CHOW, Professor, Department of Applied Biology and Chemical Technology (ABCT), PolyU (middle); Dr Vincent KENG, Associate Professor, ABCT (left); and Dr Raymond YEUNG, General Manager, Athenex HK Innovative Ltd. introduce the collaboration endeavours under the PolyU—Axis Therapeutics Joint Center for Immunotherapy
The Hong Kong Polytechnic University (PolyU) joins forces with Axis Therapeutics, a newly established joint venture by two global biopharmaceutical companies – Athenex, Inc. and Xiangxue Pharmaceutical, to foster the research and development of translational medicine by setting up a Joint Center for Immunotherapy. The Center is set to conduct collaborative research on cancer immunotherapy, with an aim to develop new cancer treatments.
A memorandum of understanding (MoU) signing ceremony for setting up the PolyU—Axis Therapeutics Joint Center for Immunotherapy was held on 18 July 2018. The MoU was signed by Ir Professor Ping-kong Alexander WAI, Vice President (Research Development) of PolyU; Dr Johnson LAU, Chairman and CEO of Athenex, Inc.; and Mr YongHui WANG, Chairman and CEO of Xiangxue Pharmaceutical and CEO of Xiangxue Life Sciences.
Addressing at the MoU signing ceremony, Mr Tze-ching CHAN, PolyU Council Chairman said this collaboration would add on PolyU’s continuous efforts and achievements in biotechnology development in the Guangdong-Hong Kong-Macau Greater Bay Area (GBA). PolyU is committed in the innovation and technology development of translational medicine, as well as transferring pioneering research to real-life applications for the benefits of mankind. Over the years, the University has been engaging in the first three new drugs developed in Hong Kong which have succeeded in getting Investigational New Drug (IND) application approval of US Food and Drug Administration (FDA).
Professor Ping-kong Alexander WAI remarked, "Partnerships between academia and industry have been very fruitful, leading to significant innovations in the form of medicines and better treatments. In this collaboration, PolyU will provide our full support for the research on novel technologies and genetics models to develop cancer immunotherapy technologies based on TCR-T and CAR-T."
Dr Johnson LAU said the companies are particularly excited about the potential synergies created by the collaboration. "The collaboration on cancer immunotherapy technology will further complement and enhance our innovation in oncology. We look forward to working closely with PolyU in bringing this novel immunotherapy technology to patients in Hong Kong and across the globe."
Mr YongHui WANG said, "We are expecting to explore a new and promising immunotherapy technology in the global scene. The new generation TCR-T, named HATac, is a breakthrough technology. The development of this technology in collaboration with our new partners holds great promise for the treatment of solid tumors. PolyU has demonstrated leadership in academia and proven to be at the forefront of collaboration with the industry to translate biotechnology research and development initiatives into products that can be developed in a commercial scale."
Please click here for the press release.
Please click here for the snapshots.
